STOCKHOLM, Sweden--(BUSINESS WIRE)--Regulatory News:
Medivir (STO:MVIRB): Consolidated net sales were SEK 14.7 (66.8) m in the period. In May, Medivir signed an agreement with Tibotec Pharmaceuticals Ltd. on hepatitis C, triggering a SEK 46.2 m (EUR 5.0 m) payment. This amount has been allocated over the assessed agreement term, with SEK 3.9 m recognized as revenue.
